An Update on The Economic Impact of Adult Immunisation
By Staff Writer
April 24, 2024
Introduction: The Value of Adult Immunisation in Health Economics
In the face of mounting pressures on global healthcare systems, adult immunisation programmes emerge as a beacon of fiscal responsibility and preventative wisdom. Recent research from the Office of Health Economics (OHE) has illuminated the substantial economic benefits these programs offer across ten diverse countries including Australia, Brazil, Germany, South Africa, Thailand, and the United States. With a return on investment of up to 19 times the initial outlay, the impact of adult immunisation stands as an exemplar of preventive healthcare, contributing to the development of a stronger and more resilient society.
Figure 1. Ten Countries Selected for this Analysis.
The Burden of Vaccine-Preventable Diseases
Vaccine-preventable diseases continue to exert a significant toll on adult populations worldwide. The OHE research underscores the heavy impact of conditions like seasonal influenza, pneumococcal disease, and others on healthcare systems. Adult immunisation programs offer a formidable shield against these diseases, averting severe health outcomes and mortality, especially among the elderly and those with chronic conditions.
Adult Immunisation Economic Impact
The economic modelling conducted by the OHE reveals that adult immunisation programs are not only health-preserving but also cost-saving. By preventing hospitalisations and emergency care, these programs can lead to net cost savings for healthcare systems. For instance, one full vaccination course can yield up to $4637 in net monetary benefits per individual.
Societal and Productivity Gains
Beyond healthcare savings, adult immunisation programs contribute to societal wealth. By preventing disease, they enable individuals to maintain productivity, reducing the economic burden on caregivers and the wider community. This aligns with the broader goals of health and economic equity, particularly benefiting underserved communities.
Figure 2. Percentage of Countries for with Evidence of Positive Impact on Value
Recommendations and Future Directions
The OHE report culminates in key recommendations, advocating for a prevention-first approach and robust funding for adult immunisation. It calls for the expansion of these programs as part of a life-course immunisation strategy, emphasising the need for further research to fill existing evidence gaps and inform policy decisions.
Conclusion
Adult immunisation programs are a cornerstone of preventive healthcare, offering unmatched economic benefits. As healthcare systems confront increasing demands, these programs stand as a testament to the power of prevention, offering a sustainable path forward for societies worldwide
💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?
A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.
With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.
Explore the details of this impactful collaboration and how it could transform HIV prevention.
🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?
With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.
The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.
Discover the pressing challenges and potential solutions in our latest article.
🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟
Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.
This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.
Read more about BioSapien’s journey and its impact on global health!
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.
